So we've gotten another garbage delivery from the

So we've gotten another garbage delivery from the multi-identity.

The "value" of any pre-revenue biotech is difficult to assign because it is the value of its intellectual property. To try to use traditional value investing measures that are appropriate for a restaurant or drug STORE is absurd.

And to claim that the company is only going to realize a couple of million income in the next year? Balderdash. The Bril-UP clinical trials can go very quickly, and it is entirely possible that milestones will be met more quickly.

But beyond that --
the company can now proceed to develop its other drugs, secure in the knowledge that Bril-UP is on the way and someone else has to do the work and pay for it.

To claim that the company will only get a couple million in the next year?
Absurd on this basis too -- because the company's development of the other forms of the drug, for other applications, means that there could be multiple other deals in the next year.

So, Mr. Soft Basher/multi-identity -- take your garbage back to your "professional" site where there may still be some sucker who believes your lies and distortions. WE do not.